

110
Chapter 8
REFERENCES
1.
Dexdor® SPC Dexmedetomidine.
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002268/WC500115631.pdf
2.
Gerlach A, Murphy C, Dasta J. An updated focused review of dexmedetomidine in adults.
Annals Pharmacother 2009; 43: 2064-2074
3.
Khan Z, Ferguson C, Jones R. Alpha
2
and imidazoline receptor agonists.
Anaesthesia 1999; 54: 146-165
4. Kamibayashi T, Maze M. Clinical uses of α
2
-adrenergic agonists.
Anesthesiology 2000; 93:1345-1349
5.
Gertler R, Brown H, Mitchell D, Silvius E. Dexmedetomidine: a novel sedative-analgesic agent.
BUMC Proceedings 2001; 14: 13-21
6.
Carollo D, Nossaman B, Ramadhyani U. Dexmedetomidine: a review of clinical applications.
Curr Opin Anesthesiol 2008; 21: 457-461
7.
Riker R, Shehabi Y, Rocha M. Dexmedetomidine vs. midazolam for sedation of critically ill patients:
a randomised trial: SEDCOM
JAMA 2009; 4: 489-499
8.
Maldonado J, Wyson A, Reitz B. Dexmedetomidine and the reduction of postoperative delirium
after cardiac surgery.
Psychosomatics 2009; 50: 206-217
9.
Pandharipande P, Pun B, Ely E. Effect of sedation with dexmedetomidine vs. lorazepam in acute
brain dysfunction in mechanically ventilated patients: the MENDS randomised controlled trial.
JAMA 2007; 12: 2699-2653
10. Tanskanen P, Kyttä J, Aantaa R. Dexmedetomidine as an anaesthetic adjuvant in patients
undergoing intracranial tumour surgery: a double-blind, randomised and placebo-controlled
study.
Br J Anaesth 2006; 97: 658-665
11. Demiraran Y, Korkut E, Tamer A, et al. The comparison of dexmedetomidine and midazolam used
for sedation of patients during upper endoscopy: a prospective, randomised study.
Can J Gastroenterol 2007; 21: 25-29
12. Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of
increasing plasma concentrations of dexmedetomidine and alfentanil in humans.
Anesthesiology 2004; 101: 744-752
13. Korogulu A, Teksan H, Sagir O. A comparison of the sedative, haemodynamic and respiratory
effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging.
Anesth Analg 2006; 103: 63-67
14. Pertovaara A, Haapalinna A, Sirviö J, Virtanen R. Pharmacological properties, central nervous
system effects and potential therapeutic applications of atipamezole, a selective α
2
-adrenoceptor
antagonist.
CNS Drug Reviews 2005; 3: 273-288